Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616100 | 0.93 | DNMT1 (0.40) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL275907 | 0.93 | DNMT1 (0.40) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL29368065 | 0.93 | DNMT1 (0.40) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL30436853 | 0.92 | DNMT1 (0.39) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL8595804 | 0.92 | DNMT1 (0.39) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL5107 | 0.91 | ALDH1A1 (0.44) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL146878 | 0.91 | ALDH1A1 (0.44) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL29350037 | 0.91 | ALDH1A1 (0.44) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL29496111 | 0.91 | ALDH1A1 (0.44) | GPR84DNMT1WDR5ALDH1A1TDP1 | |
| SCHEMBL10323632 | 0.91 | ALDH1A1 (0.44) | GPR84DNMT1WDR5ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7498354-B2 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | OSI PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7419995-B2 | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1883638-A1 | PYRROLO [2,3-D] IMIDAZOLES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | OSI Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006107756-A1 | PYRROLO [2,3-D] IMIDAZOLES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | OSI PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223799-A1 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | OSI PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223799-A1 | Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders | PPOX, VHL, TP53 | GPR84 4656/4885DNMT1 83/4885WDR5 2120/4885 |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | GPR84 2915/4885DNMT1 2194/4885WDR5 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.